Tag: U.K.
-
Trial Shows Smartphone App Effective for Weight Loss
Food scientists at University of Leeds in the U.K. found a smartphone app helped participants in a clinical trial better manage their food intake and lose weight compared to a food diary on a Web site or on paper. The findings of the team led by Leeds’s epidemiology professor Janet Cade, appear online in today’s…
-
Modern Methods Examined for Beer from Victorian Barley
Researchers at the John Innes Center, a plant science research institute in Norwich, U.K., are investigating the commercial potential of brewing beer from Chevallier, a classic variety of barley grown during Britain’s Victorian era in the second half of the 19th century. A grant of £250,000 ($US 384,000) from the U.K.’s Biotechnology and Biological Sciences…
-
Fruit Juice Infusion Cuts Chocolate Fat Content in Half
Chemistry researchers at University of Warwick in the U.K. developed a process for keeping the desirable taste and texture of chocolate while sharply reducing its fat content. Warwick’s Stefan A. F. Bon described the process yesterday in a presentation at a meeting of the American Chemical Society in New Orleans. Bon and colleagues study colloidal…
-
Synthetic Tissue Created with Water, Lipids, 3-D Printing
Biochemical researchers at University of Oxford in the U.K. developed materials from networks of water droplets inside lipid films to perform functions similar to human tissue. The team led by Oxford chemistry professor Hagan Bayley published its findings as the cover story in this week’s issue of the journal Science (paid subscription required). The researchers…
-
New International Food Allergy Management Study Underway
An international study of food allergy is underway, headed by University of Manchester in the U.K., that aims to develop an evidence-based management process for food manufacturers, as well as guidelines for pregnant women, infants, and allergy sufferers. The four-year €9 million ($US 11.6 million) Integrated Approaches to Food Allergen and Allergy Risk Management or…
-
AstraZeneca Licenses Messenger RNA Therapy Technology
The pharmaceutical company AstraZeneca based in London is licensing genomic technology from Moderna Therapeutics, a biotechnology company in Cambridge, Massachusetts to develop treatments for heart disease, metabolic disorders, and cancer. The five-year deal has potential payout to Moderna of $420 million. Moderna Therapeutics harnesses messenger RNA, nucleic acids related to DNA that leave the cell…
-
Clinical Trial to Test Stroke Hemorrhage Treatment
A clinical trial at University of Nottingham and other sites in the U.K. will test the drug tranexamic acid as a treatment for hemorrhaging in the brain caused by a stroke. The trial is funded by a £2.6 million ($3.9 million) grant from the Health Technology Assessment Programme of the U.K.’s National Institute for Health…
-
AstraZeneca Consolidates Research in U.K. and U.S.
The pharmaceutical company AstraZeneca will consolidate its research operations at three main hubs in its U.K. home base, as well as the U.S. and continental Europe. The four-year plan, which includes moving its corporate headquarters, is expected to cost the company $1.4 billion and result in a reduction of some 1,600 jobs, mainly in the…
-
Software Advances Improve Cardiac Ultrasound Images
Biomedical engineers at University of Oxford in the U.K. developed software that they say enhances the ultrasound image quality of the heart. The original research, funded by the U.K.’s Engineering and Physical Sciences Research Council, led to a start-up company to commercialize the technology, which is on display today at the Healthcare Innovation Expo 2013…
-
University, Companies to Partner on Wound Care Sensors
Researchers at University of Strathclyde in Glasgow, Scotland and Hamad Medical Corporation in Qatar are collaborating on development of sensors that monitor wound dressings, starting with a product created by a spin-off company from Strathclyde. The three-year project is funded by the Qatar National Research Fund, but financial aspects of the agreement were not disclosed.…